Sugi Predict

Sugi Predict / Compounds / SCHEMBL68181

SCHEMBL68181

SCHEMBL68181

O=[N+]([O-])c1ccc(Cl)cc1CO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.58
▸ MAPK1 P28482 1/20 0.58
▸ KMT2A Q03164 4/20 0.56
▸ MEN1 O00255 3/20 0.56
▸ ALDH1A1 P00352 5/20 0.52
▸ POLB P06746 3/20 0.52
▸ MAPT P10636 1/20 0.52
▸ NOS3 P29474 1/20 0.48
▸ NOS1 P29475 1/20 0.48
▸ NOS2 P35228 1/20 0.48
▸ CYP1A2 P05177 2/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ CYP2C19 P33261 2/20 0.47
▸ LMNA P02545 2/20 0.46
▸ VCAM1 P19320 1/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ ATM Q13315 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6525417 0.92 KMT2A (0.50) TSHRMAPK1KMT2AMEN1ALDH1A1
SCHEMBL20362277 0.85 TSHR (0.46) TSHRMAPK1KMT2AMEN1ALDH1A1
SCHEMBL67536 0.85 MAPK1 (0.53) TSHRMAPK1KMT2AMEN1ALDH1A1
SCHEMBL67864 0.83 MAPK1 (0.60) TSHRMAPK1KMT2AMEN1ALDH1A1
SCHEMBL27273104 0.83 MAPK1 (0.60) TSHRMAPK1KMT2AMEN1ALDH1A1
SCHEMBL2949639 0.83 TSHR (0.60) TSHRMAPK1KMT2AMEN1ALDH1A1
SCHEMBL7488039 0.82 ALDH1A1 (0.50) TSHRMAPK1KMT2AMEN1ALDH1A1
SCHEMBL6377973 0.81 MAPK1 (0.58) TSHRMAPK1KMT2AMEN1ALDH1A1
SCHEMBL68713 0.81 TSHR (0.58) TSHRMAPK1KMT2AMEN1ALDH1A1
SCHEMBL9191570 0.81 MAPK1 (0.58) TSHRMAPK1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4400166-A2 METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS Contraline, Inc. (US) 2024-07-17 — — EP claimed
EP-3565484-B1 COMPOSITIONS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS CONTRALINE INC (US) 2024-04-03 — — EP claimed
CN-114685920-B Degradable packaging material and synthesis method thereof 安徽康采恩包装材料有限公司 2023-09-26 — — CN claimed
CN-114685920-A Degradable packaging material and synthesis method thereof 安徽康采恩包装材料有限公司 2022-07-01 — — CN claimed
EP-3565484-A1 METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS Contraline, Inc. (US) 2019-11-13 — — EP claimed
WO-2018129369-A1 METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS Contraline, Inc. (US) 2018-07-12 — — WO claimed
US-20180185096-A1 METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS Contraline, Inc. 2018-07-05 — — US claimed
US-12383421-B2 Contraceptive devices Contraline, Inc. (US) 2025-08-12 — — US disclosed
US-12275686-B2 NO donor compound, preparation method thereof, pharmaceutical composition comprising same, and use thereof SOUTHEAST UNIVERSITY (CN) 2025-04-15 — — US disclosed
CN-116675620-B NO donor compound, preparation method, pharmaceutical composition and application thereof 东南大学 2025-01-10 — — CN disclosed
EP-4484409-A1 NO DONOR COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF Southeast University (CN) 2025-01-01 — — EP disclosed
US-20240409500-A1 NO DONOR COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF SOUTHEAST UNIVERSITY (CN) 2024-12-12 — — US disclosed
EP-4400166-A2 METHODS FOR IMPLANTING AND REVERSING STIMULI-RESPONSIVE IMPLANTS Contraline, Inc. (US) 2024-07-17 — — EP disclosed
EP-0406958-A2 Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1991-01-09 — — EP disclosed
EP-0371564-A2 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1990-06-06 — — EP disclosed
EP-0252503-A1 Aminoimidazoquinoline derivatives Bristol-Myers Squibb Company (US) 1988-01-13 — — EP disclosed
US-4701459-A 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation BRISTOL-MYERS COMPANY (US) 1987-10-20 — — US disclosed
US-4495101-A Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1985-01-22 — — US disclosed
US-4268510-A DEMETHANIZATION, METABOLISM, RUMEN IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1981-05-19 — — US disclosed
EP-0010348-A1 Heterocyclic trichloromethyl derivatives, process for their preparation and their use IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1980-04-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12275686-B2 NO donor compound, preparation method thereof, pharmaceutical composition comprising same, and use thereof HIF1A, NOS1, NOS2 TSHR 4509/4885MAPK1 1458/4885KMT2A 2397/4885
US-20240409500-A1 NO DONOR COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF HIF1A, NOS1, NOS2 TSHR 4509/4885MAPK1 1458/4885KMT2A 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.